Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...
A woman is suing a fertility clinic for transferring another couple's embryo into her uterus. They realized the error when ...
The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...
Shares of Hims & Hers (NYSE: HIMS) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the ...
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $36.43, ...
Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...
BTIG analyst David Larsen raised the firm’s price target on Hims & Hers (HIMS) to $85 from $35 and keeps a Buy rating on the shares. The ...
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...